CHP Merger CHPMU = 1C, 1/2W
IPO trust 300mm including overalot.
On November 26, 2019, consummated an initial public offering (the “IPO”) of 30,000,000 units - includes the partial exercise of the underwriters’ option to purchase an additional 4,125,000 Units at the initial public offering price to cover over-allotments, and a private placement with CHP Acquisition Holdings LLC (the “Sponsor”) of 8,000,000 private placement warrants at a price of $1.00 per warrant (the “Private Placement”). The net proceeds from the IPO together with certain of the proceeds from the Private Placement, $300,000,000 in the aggregate (the “Offering Proceeds”), were placed in a trust account established for the benefit of the Company’s public stockholders and the underwriters of the IPO
J.P. Morgan Credit Suisse Morgan Stanley
SUMMIT, N.J., Nov. 22, 2019 /PRNewswire/ -- CHP Merger Corp. (the "Company"), a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced the pricing of its initial public offering of 27,500,000 units at $10.00 per unit. The Company's sponsor is an affiliate of Concord Health Partners ("Concord"), a healthcare-focused investment firm with a strategic approach that aligns interests between investors and portfolio companies.
The units will be listed on the Nasdaq ("Nasdaq") and trade under the ticker symbol "CHPMU" beginning November 22, 2019. Each unit consists of one share of Class A common stock of the Company and one-half of one warrant. Each whole warrant entitles the holder thereof to purchase one share of the Company's Class A common stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on the Nasdaq under the symbols "CHPM" and "CHPMW," respectively.
The offering is expected to close on November 26, 2019, subject to customary closing conditions.
J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC and Morgan Stanley & Co. LLC. are acting as joint book-running managers for the offering. The Company has granted the underwriters a 45-day option to purchase up to 4,125,000 additional units at the initial public offering price to cover over-allotments, if any.